Ventilator Associated Pneumonia. ICU Fellowship Training Radboudumc
|
|
- Sylvia Harrington
- 5 years ago
- Views:
Transcription
1 Ventilator Associated Pneumonia ICU Fellowship Training Radboudumc
2 Attributable mortality VAP Meta-analysis of individual patient data from randomized prevention studies Attributable mortality mainly results from longer stay in the ICU Melsen WG. Lancet 2013
3
4 The problem Clinical criteria Antibiotics No antibiotics Sensitivity 69% Specificity 75% Selection multiresistant micro-organisms Inadequate treatment increases mortality The importance of quantitative cultures is not consistent
5 Incidence of VAP? Prospective cohort & nonrandomized trials (N = 38) Control arms in randomized trials (N = 51) Safdar N. Crit Care Med 2005;33:
6 ICU acquired infection Potential Pathogenic M.O. Reservoir Other patient Digestive tract Surroundings Colonisation Infection
7 Pathophysiology VAP N = 64 Tracheal aspirate 17 PPMO (85%) Gastric aspirate 6 PPMO (20%) Pneumonia N = PPMO Bonten MJ. Chest 1994;105:
8 Exogenous source Oral colonisation Endogenous source Accumulation of secretions above cuff Colonization of Trachea Pneumonia
9 Bed head elevation Niel-Weise BS. Crit Care 2011;15:R111
10 A group of 22 experts recommended elevating the head of the bed of mechanically ventilated patients to a 20 to 45 degrees position and preferably in a 30 degrees position as long as it does not pose risks or conflicts with other nursing tasks, medical interventions or patients wishes. Niel-Weise BS. Crit Care 2011;15:R111
11 ET modifications Silver sulfadiazine
12 Subglottic drainage N Control Study P-value Comment Mahul General ICU 29,1 13 < 0,05 No BAL or PSB Valles General ICU 39.6/ /1000 0,03 BAL/PSB Kollef Cardiac ICU 8,2% 5% 0,238 No BAL or PSB Smulders General ICU 16% 4% 0,014 No BAL or PSB Lorente General ICU 22,1% 7,9% 0,001 No BAL or PSB We recently finished a RCT on subglottic drainage after tracheostomy
13 Subglottic drainage 40 Subglottic drainage (n=169) p=0.02 Control (n=164) p=0.01 Incidence, % p= VAP total VAP early VAP late 6 ARR 11% < 5 days 5 days Lacherade JC. Am J Respir Crit Care Med 2010; 182:
14 Lacherade JC. Am J Respir Crit Care Med 2010; 182: Secondary outcomes , ,1 11,6 8,0 7,0 11,0 11,0 3 4,5 0 PED, % Tracheostomy, % MV, d LOS, d No difference in mortality
15 Subglottic drainage Reduces LOS and duration of MV but not mortality Muscedere J. Crit Care Med 2011
16 SDD and SOD NS 30 NS 27,5 26,6 26,9 Crude mortality (%) After correction for baseline differences absolute mortality reduction with SDD and SOD of 3.5 and 2.9% respectively 0 Control (N = 1990) SOD (N = 1904) SDD (N = 2045) de Smet AMGA. N Engl J Med 2009;360:20-31
17 Colonisation with resistant Gr- organisms 20 Ceftazidime - rectal isolates % colonised Time (months) 24Oostdijk EAN. Am J Respir Crit Care Med 2010;181:
18 Colonisation with BMRO de Smet AMGA. Lancet Inf Dis 2011
19 Oral decontamination and antibiotic resistance SDD SOD 30 P < P < 0.42 P < ,5 24,1 25,4 15 7,5 0 11,8 5,6 5,9 4,6 Aminogl resistant Gr - D 28 mortality Bacteremia N = In both groups gradual resistance increase Oostdijk EAN. JAMA 2014
20 SDD Meta-analysis SOD Chlorhexidine ( ) Favours SOD Favours Control ( ) ( ) Favours SDD Favours Control Favours SDD Favours Control Price R. BMJ 2014;348:g2197
21 Morrow LE. Am J Respir Crit Care Med 2010;182: Probiotics and VAP prevention RCT - N = oral/gastric Lactobaccilus rhamnosus 40 Probiotics Control P = P = VAP 0 Closttridium Difficile
22 Early vs late tracheotomy for VAP prevention N = 419 Early = 6-8 D Late = D Early Late P = VAP % 0 MV free days D 28 No difference in mortality JAMA 2010;303:
23 69% 57%
24 Diagnostic strategy in oncology patients with ARF Azoulay E. Am J Respir Crit Care Med 2010;182:
25 Conclusion In oncology patients with ARF early FO- BAL does not increase the need for MV Approximately 15-20% of diagnoses stems from FO-BAL Non-invasive strategy is very successful and likely so in the near future Up-to-date early FO-BAL still indicated but balance certainly shifted towards noninvasive strategy Azoulay E. Am J Respir Crit Care Med 2010;182:
26 Possible strategy Clinical suspicion CPIS > 6 (moderate sensitivity) Quantitative cultures Start antibioticics role of biomarkers appears limited after hours Diagnosis VAP likely Antibiotics 7-10 D PCT? Diagnosis VAP? Alternative diagnosis? Individual decission TREM- 1 VAP unlikely Stop antibiotics Fagon JY. Crit Care 2011;15:130
27 Antibiotic duration N = 401 Antibiotics 8 D Antibiotics 15 D 30 28, ,8 17, ,1 8,7 0 Mortality (%) Antibiotic free days (D) Recurrence (%) Higher relapse rate with pseudomonas and acinetobacter with shorter ab duration Chastre J. JAMA 2003;290:
28 Inhalation antibiotics First Phase II RCT of i.v. versus inhaled ceftazidime and amikacin N = 40 - VAP with susceptible or intermediate pseudomonas strains After 8 dyas of treatment success rate in inhalation group 70% and i.v. 55% (NS) Acquisition of resistance only in i.v. group Lu Q. Am J Respir Crit Care Med 2011;in press
29 Inhaled antibiotics and MDRO s Double-blind, randomized, placebo-controlled trial (N = 42) MV patients with high risk for MDRO Purulent sputum with + gram stain and CPIS 6 Placebo versus inhaled antibiotics (based on gram stain and/or amikacin) every 8 hrs for 14 D - systemic antibiotics by physician Palmer LB. Am J Respir Crit Care Med 2014;189:
30 Inhaled antibiotics and MDRO s Other MDRO 30 Number tracheal isolates at start Control 20 7 Inhaled antibiotics No. of eradicated organisms present at randomization No. of patients with eradication of resistant MO IA Placebo P-value 96% (26/27) 88% (14/16) 9% (2/23) < % (1/11) < Significantly less development of resistance to systemic antibiotics in inhaled antibiotics group Palmer LB. Am J Respir Crit Care Med 2014;189:
31 Aspergillus infection Bimodal peak During mucosal breakdown/prolonged granulocytopenia and during treatment for GVHD 1 year incidence after allogeneic HSCT of 12% and mortality of 50-80% Positive culture of tracheal aspirate and/or BAL + antigen rise sufficient to start empirical treatment in right clinical/ radiological circumstances
32 Epidemiology (1) Increased use of HSCT practices with high risk of GVHD (HLA mismatch and reduced intensity conditioning) T-cell-depleted and CD34-selected stem cells reduce GVHD but have higher risk of delayed immune reconstitution Antifungal prophylaxis in preengraftment period Fewer early fungal infections - increasing late infections
33
34 Epidemiology (2) Classical radiological signs in neutropenic patients are now often absent Serum galactomannan test less sensitive in non-neutropenic patients Increased incidence of non-aspergillus moulds
35 Nodular infiltrate Halo sign
36 Aspergillus after H1N1 N = 40 Proven H1N1 infection in the ICU N = 31 (77%) No Invasive Pulmonary Aspergillosis N = 9 (23%) Invasive Pulmonary Aspergillosis Proven N = 5 Probable N = 5 Use of corticosteroids significant risk factor Wauters J. Intensive Care Med 2012;38:
37 Cerebral aspergillosis in ICU patients AspICU study (563 adult patients with + direct Asp test on any body site) N = 10 (1.8%) - none primarily diagnosed with invasive sinus or pulmonary aspergillosis Often multiple lesions - none of the patients had neurological signs One patient extensive meningitis Mortality 9/10 despite antifungal treatment Spapen H. Int J Antimicrob Agents 2014;43:
38
39 Conclusions Gold standard diagnostic strategy still unclear - Role of biomarkers limited Invasive strategy in immunocompromised patients may be unnecessary Prevention of tracheal colonisation apparently successful Role of inhaled antibiotics still unclear
Ventilator Associated Pneumonia. ICU Fellowship Training Radboudumc
Ventilator Associated Pneumonia ICU Fellowship Training Radboudumc Attributable mortality VAP Meta-analysis of individual patient data from randomized prevention studies Attributable mortality mainly results
More informationComplications after HSCT. ICU Fellowship Training Radboudumc
Complications after HSCT ICU Fellowship Training Radboudumc Type of HSCT HSCT Improved outcome due to better HLA matching, conditioning regimens, post transplant supportive care Over one-third have pulmonary
More informationVentilator Associated
Ventilator Associated Pneumonia: Key and Controversial Issues Christopher P. Michetti, MD, FACS Inova Fairfax Hospital, Falls Church, VA Forrest Dell Moore, MD, FACS Banner Healthcare System, Phoenix,
More informationDiagnosis of Ventilator- Associated Pneumonia: Where are we now?
Diagnosis of Ventilator- Associated Pneumonia: Where are we now? Gary French Guy s & St. Thomas Hospital & King s College, London BSAC Guideline 2008 Masterton R, Galloway A, French G, Street M, Armstrong
More informationANWICU knowledge
ANWICU knowledge www.anwicu.org.uk This presenta=on is provided by ANWICU We are a collabora=ve associa=on of ICUs in the North West of England. Permission to provide this presenta=on has been granted
More informationInvasive Pulmonary Aspergillosis in
Infection & Sepsis Symposium Porto, April 1-3, 2009 Invasive Pulmonary Aspergillosis in Non-Immunocompromised Patients Stijn BLOT, PhD General Internal Medicine & Infectious Diseases Ghent University Hospital,
More informationHEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY
HEALTHCARE-ASSOCIATED PNEUMONIA: EPIDEMIOLOGY, MICROBIOLOGY & PATHOPHYSIOLOGY David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics, & Epidemiology Associate Chief Medical Officer, UNC Health
More informationHEALTHCARE-ASSOCIATED PNEUMONIA: DIAGNOSIS, TREATMENT & PREVENTION
HEALTHCARE-ASSOCIATED PNEUMONIA: DIAGNOSIS, TREATMENT & PREVENTION David Jay Weber, M.D., M.P.H. Professor of Medicine, Pediatrics, & Epidemiology Associate Chief Medical Officer, UNC Health Care Medical
More informationGuidelines 2017 for the management of hospitalacquired pneumonia (HAP) and. ventilator-associated. pneumonia (VAP)
Guidelines 2017 for the management of hospitalacquired pneumonia (HAP) and ventilator-associated Modifiez le style des sous-titres du masque pneumonia (VAP) Filip Moerman Présentation pour les soins int
More informationVAP Definitions. CDC New Approach to VAP Surveillance. Conflict of Interest Disclosure Robert M Kacmarek. Artificial Airways, Cuffs, Bioflim and VAP
Conflict of Interest Disclosure Robert M Kacmarek Artificial Airways, Cuffs, Bioflim and VAP Bob Kacmarek PhD, RRT Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts 9-14-18
More informationTop 5 papers in clinical mycology
Top 5 papers in clinical mycology Dirk Vogelaers Department of General Internal Medicine University Hospital Ghent Joint symposium BVIKM/BSIMC and SBMHA/BVMDM Influenza-associated aspergillosis in critically
More informationNew Surveillance Definitions for VAP
New Surveillance Definitions for VAP 2012 Critical Care Canada Forum Toronto Dr. John Muscedere Associate Professor of Medicine, Queen s University Kingston, Ontario Presenter Disclosure Dr. J. G. Muscedere
More informationVAP Prevention bundles
VAP Prevention bundles Dr. Shafiq A.Alimad MD Head of medical department at USTH YICID workshop, 15-12-2014 Care Bundles What are they & why use them? What are Care Bundles? Types of Care Bundles available
More informationAmerican College of Surgeons Critical Care Review Course 2012: Infection Control
American College of Surgeons Critical Care Review Course 2012: Infection Control Overview: I. Central line associated blood stream infection (CLABSI) II. Ventilator associated pneumonia (VAP) I. Central
More informationIs pre-emptive therapy a realistic approach?
Is pre-emptive therapy a realistic approach? J Peter Donnelly PhD, FRCPath Department of Haematology Radboud University Nijmegen Medical Centre Nijmegen, The Netherlands Is pre-emptive therapy a realistic
More informationAntisepsis Bath and Oral.. Should We Change Practice? DR AZMIN HUDA ABDUL RAHIM
Antisepsis Bath and Oral.. Should We Change Practice? DR AZMIN HUDA ABDUL RAHIM Chlorhexidine Exposure in ICU Chlorhexidine gluconate Long acting topical antiseptic In use since 1954 Water soluble Remains
More informationIntracheal antibiotics administration
Intracheal antibiotics administration Jean Chastre, M.D. www.reamedpitie.com Disclosure Conflicts of interest: Consulting or Lecture fees: Bayer, Pfizer, Cubist/Merck, Basilea, Kenta/Aridis, Roche, AstraZeneca/Medimmune
More informationUsefulness of Procalcitonin in the management of Infections in ICU. P Damas CHU Sart Tilman Liège
Usefulness of Procalcitonin in the management of Infections in ICU P Damas CHU Sart Tilman Liège Procalcitonin Peptide 116 AA Produced by parenchymal cells during «sepsis»: IL1, TNF, IL6 : stimulators
More informationVentilator associated events, conditions and prevention of VAP. Dr.Pratap Upadhya
Ventilator associated events, conditions and prevention of VAP Dr.Pratap Upadhya Introduction Pathogenesis of vap Diagnosis of vap Ventilator-Associated Events: New Terminology and Its Relationship to
More informationECMM Excellence Centers Quality Audit
ECMM Excellence Centers Quality Audit Person in charge: Department: Head of Department: Laboratory is accredited according to ISO 15189 (Medical Laboratories Requirements for quality and competence) Inspected
More informationNosocomial Pneumonia. <5 Days: Non-Multidrug-Resistant Bacteria
Nosocomial Pneumonia Meredith Deutscher, MD Troy Schaffernocker, MD Ohio State University Burden of Hospital-Acquired Pneumonia Second most common nosocomial infection in the U.S. 5-10 episodes per 1000
More informationThe Potential For Microbiome Modification In Critical Illness. Deborah Cook
The Potential For Microbiome Modification In Critical Illness Deborah Cook To review Objectives The microbiome & concepts about its modification during critical illness Interventions Predisposition to
More informationMechanical Ventilation
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 33: Mechanical Ventilation Authors C. Landelle, PharmD, PhD D. Pittet, MD, MS Chapter Editor Gonzalo Bearman, MD, MPH, FACP, FSHEA, FIDSA Topic Outline
More informationYear in Review Intensive Care Training Program Radboud University Medical Centre Nijmegen
Year in Review 2013 Intensive Care Training Program Radboud University Medical Centre Nijmegen Contents ARDS Ventilator associated pneumonia Tracheostomy and endotracheal intubation Enteral feeding Fluid
More informationTHE MICROBIOLOGICAL PROFILE OF VENTILATOR ASSOCIATED PNEUMONIA.
THE MICROBIOLOGICAL PROFILE OF VENTILATOR ASSOCIATED PNEUMONIA. Dr. Poonam C. Sharma, Dr. S. S. Raut, Dr. S. R. More, Dr. V. S. Rathod, Dr. V. M. Gujar. 1. Post Graduate Student, Department of Microbiology,
More informationMarcos I. Restrepo, MD, MSc, FCCP
Thank you for viewing this presentation. We would like to remind you that this material is the property of the author. It is provided to you by the ERS for your personal use only, as submitted by the author.
More informationASPERGILLOSIS IN THE NON-NEUTROPENIC HOST
ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST Dr J Garbino University Hospital Geneva ASPERGILLOSIS IN THE NON-NEUTROPENIC HOST INTRODUCTION SWISS ASPERGILLOSIS SURVEY IN THE NON-NEUTROPENIC HOST Introduction
More informationControversies in management: prophylaxis or diagnostics
5 th Advances Against Aspergillosis Controversies in management: prophylaxis or diagnostics Caveats in the use of biological markers for early diagnosis Drosos E. Karageorgopoulos, MD Researcher, Alfa
More informationGuess or get it right?
Guess or get it right? Antimicrobial prescribing in the 21 st century Robert Masterton Traditional Treatment Paradigm Conservative start with workhorse antibiotics Reserve more potent drugs for non-responders
More informationVAP in COPD patients. Ignacio Martin-Loeches. St James s University Hospital. Trinity Centre for Health Sciences. Dublin Ireland.
VAP in COPD patients Ignacio Martin-Loeches St James s University Hospital. Trinity Centre for Health Sciences. Dublin Ireland. Outline Pathophysiology Is enough information? COPD trends in ICU How do
More informationKIMBERLY-CLARK* MICROCUFF* Endotracheal Tube.. Revolutionary cuff material designed to reduce micro-aspiration
KIMBERLY-CLARK* MICROCUFF* Endotracheal Tube.. Revolutionary cuff material designed to reduce micro-aspiration Ventilator-Associated Pneumonia VAP is a major clinical concern...... associated with high
More informationA NEW direction for subglottic secretion management
A NEW direction for subglottic secretion management The SIMEX Subglottic Aspiration System, cuff M and cuff S are the most advanced solution for the aspiration of subglottic secretion, featuring all new
More informationOutline NEW DIAGNOSTIC TOOLS WHY? WHICH TESTS? WHEN TO USE THEM? Documented IFI
New Developments and Challenges in Diagnostics of Invasive Fungal Infections O. Marchetti, MD Infectious Diseases Service, Department of Medicine, CHUV and University of Lausanne, Switzerland Workshop
More informationPrevention of Nosocomial Infections in Critically Ill Patients with Lactoferrin (PREVAIL) Study
Prevention of Nosocomial Infections in Critically Ill Patients with Lactoferrin (PREVAIL) Study A Randomized Double Blind Phase II Study Dr. John Muscedere, Queen s University, Kingston, Canada Co-Investigators:
More informationSaudi Journal of Medical and Pharmaceutical Sciences. DOI: /sjmps. Review Article. Available Online:
DOI: 10.21276/sjmps Saudi Journal of Medical and Pharmaceutical Sciences Scholars Middle East Publishers Dubai, United Arab Emirates Website: http://scholarsmepub.com/ ISSN 2413-4929 (Print) ISSN 2413-4910
More informationCHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement
CHEST VOLUME 117 / NUMBER 4 / APRIL, 2000 Supplement Evidence-Based Assessment of Diagnostic Tests for Ventilator- Associated Pneumonia* Executive Summary Ronald F. Grossman, MD, FCCP; and Alan Fein, MD,
More informationClinical Practice Management Guideline for Ventilator-Associated Pneumonia: Diagnosis, Treatment & Prevention
Clinical for Ventilator-Associated Pneumonia: Diagnosis, Treatment & Prevention Background Ventilator-associated pneumonia (VAP), a pneumonia that develops 48hrs after initiation of mechanical ventilation,
More informationAspergillosis in the critically ill patient
Aspergillosis in the critically ill patient José Artur Paiva Director of Emergency and Intensive Care Department Centro Hospitalar São João Porto Associate Professor of Medicine University of Porto Infection
More informationBIP Endotracheal Tube
Bactiguard Infection Protection BIP Endotracheal Tube For prevention of healthcare associated infections Ventilator associated pneumonia Infections of the respiratory tract are serious and common healthcare
More informationHospital-acquired Pneumonia
Hospital-acquired Pneumonia Hospital-acquired pneumonia (HAP) Pneumonia that occurs at least 2 days after hospital admission. The second most common and the leading cause of death due to hospital-acquired
More informationCurrent Concepts in VAP: Stress Ulcer Prophylaxis & Probiotics. Deborah Cook
Current Concepts in VAP: Stress Ulcer Prophylaxis & Probiotics Deborah Cook Objectives VAP The Old: Gastropulmonary route of infection The New: Microbiome modification Role of acid suppression Influence
More informationFrom the labo to the ICU: Surveillance cultures in daily ICU practice. Pieter Depuydt MD PhD Dept. Intensive Care Ghent University Hospital
From the labo to the ICU: Surveillance cultures in daily ICU practice Pieter Depuydt MD PhD Dept. Intensive Care Ghent University Hospital Question 1: What is the current practice of surveillance cultures
More informationTIMM 2013 Role of non-culture biomarkers for detection of fungal infections
TIMM 2013 Role of non-culture biomarkers for detection of fungal infections Tom Rogers Clinical Microbiology, Trinity College Dublin Tom Rogers, TCD & St James s Hospital Dublin, Ireland FACTORS INFLUENCING
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationJean CARLET, M.D. Head of the Research and Safety Program The French National Authority for Health (HAS)
ZERO VAP Dream, mystification, or reality? Jean CARLET, M.D. Head of the Research and Safety Program The French National Authority for Health (HAS) National Prevalence surveys 2 5 2 438 474 (95%) beds
More informationVentilator Associated Pneumonia: New for 2008
Ventilator Associated Pneumonia: New for 2008 Jeanine P. Wiener-Kronish, MD Henry Isaiah Dorr Professor of Research and Teaching in Anaesthetics and Anaesthesia Department of Anesthesia and Critical Care
More informationCommunity Acquired & Nosocomial Pneumonias
Community Acquired & Nosocomial Pneumonias IDSA/ATS 2007 & 2016 Guidelines José Luis González, MD Clinical Assistant Professor of Medicine Outline Intro - Definitions & Diagnosing CAP treatment VAP & HAP
More informationP. aeruginosa: Present therapeutic options in Intensive Care. Y. Van Laethem (CHU St-Pierre & Université libre de Bruxelles, Brussels, Belgium)
P. aeruginosa: Present therapeutic options in Intensive Care Y. Van Laethem (CHU St-Pierre & Université libre de Bruxelles, Brussels, Belgium) Activity vs Pseudomonas aeruginosa Pseudomonas aeruginosa
More informationKeywords: hospital-acquired pneumonia, healthcare-associated pneumonia, evidence-based guidelines, prevention, diagnosis, antimicrobial treatment ...
Journal of Antimicrobial Chemotherapy (2008) 62, 5 34 doi:10.1093/jac/dkn162 Advance Access publication 29 April 2008 Guidelines for the management of hospital-acquired pneumonia in the UK: Report of the
More informationPREVALENCE PATTERN OF MORBIDITY AND MORTALITY IN VENTILATION ASSOCIATED PNEUMONIA (VAP) PATIENTS OF INTENSIVE CARE UNIT (ICU) IN MAHARASHTRA REGION.
Original research article International Journal of Medical Science and Education pissn- 2348 4438 eissn-2349-3208 PREVALENCE PATTERN OF MORBIDITY AND MORTALITY IN VENTILATION ASSOCIATED PNEUMONIA (VAP)
More informationAntimicrobial Stewardship in Community Acquired Pneumonia
Antimicrobial Stewardship in Community Acquired Pneumonia Medicine Review Course 2018 Dr Lee Tau Hong Consultant Department of Infectious Diseases National Centre for Infectious Diseases Scope 1. Diagnosis
More informationEMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS
EMERGING FUNGAL INFECTIONS IN IMMUNOCOMPROMISED PATIENTS DR LOW CHIAN YONG MBBS, MRCP(UK), MMed(Int Med), FAMS Consultant, Dept of Infectious Diseases, SGH Introduction The incidence of invasive fungal
More informationWHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS?
WHICH ANTIFUNGAL AGENT IS THE CHOICE FOR SUSPECTED FUNGAL INFECTIONS? Assoc. Prof. Dr. Serkan SENER Acibadem University Medical School Department of Emergency Medicine, Istanbul Acibadem Ankara Hospital,
More informationHow Can We Prevent Invasive Fungal Disease?
How Can We Prevent Invasive Fungal Disease? Chris Kibbler Professor of Medical Microbiology University College London And Royal Free Hospital, London, UK Invasive Aspergillosis 2 - Acquisition Preventive
More informationChallenges in Diagnosis, Surveillance and Prevention of Ventilator-associated pneumonia
Challenges in Diagnosis, Surveillance and Prevention of Ventilator-associated pneumonia Massachusetts Coalition for the Prevention of Errors November 6, 2008 Michael Klompas MD, MPH, FRCPC Brigham and
More informationHerpes virus reactivation in the ICU. M. Ieven BVIKM
Herpes virus reactivation in the ICU M. Ieven BVIKM 07.04.2011 Introduction: Viruses identified in critically ill ICU patients Viral diseases have recently been the subject of numerous investigations in
More informationTOP PAPERS in MEDICAL MYCOLOGY Laboratory Diagnosis Manuel Cuenca-Estrella Abril 2018
TOP PAPERS in MEDICAL MYCOLOGY Laboratory Diagnosis Manuel Cuenca-Estrella Abril 2018 MCE01 Conflict of interest disclosure In the past 5 years, M.C.E. has received grant support from Astellas Pharma,
More informationCytomegalovirus in critically ill patients
! Cytomegalovirus in critically ill patients Frédéric Pène Medical ICU, Hôpital Cochin, AP-HP, Paris, France Université Paris Descartes, Sorbonne Paris Cité Institut Cochin, Inserm U1016, CNRS UMR-8104
More informationHow to prevent Infections in Patients undergoing allo-hsct?
How to prevent Infections in Patients undergoing allo-hsct? Olaf Penack EBMT Course, 29 Sept 1 Oct 2014, Naples, Italy #EBMT2014 www.ebmt.org Prevention of Infections Epidemiology and risk factors for
More informationChapter 22. Pulmonary Infections
Chapter 22 Pulmonary Infections Objectives State the incidence of pneumonia in the United States and its economic impact. Discuss the current classification scheme for pneumonia and be able to define hospital-acquired
More informationTargeted literature review:
Targeted literature review: What are the key infection prevention and control recommendations to inform a minimising ventilator associated pneumonia (VAP) quality improvement tool? Part of HAI Delivery
More informationEffects of Systematic Oral Care in Critically Ill Patients: a Multicenter Study
Effects of Systematic Oral Care in Critically Ill Patients: a Multicenter Study NANCY J. AMES, RN, PhD, CCRN with Pawel Sulima, Jan M. Yates, Linda McCullagh, Sherri L. Gollins, Karen Soeken, and Gwenyth
More informationVentilator-associated pneumonia
Respirology (2009) 14 (Suppl. 2) S51 S58 doi: 10.1111/j.1400-1843.2009.01577.x CHAPTER VIII Ventilator-associated pneumonia SUMMARY Ventilator-associated pneumonia is a pneumonia that develops initially
More informationPrimary prophylaxis of invasive fungal infection in patients with haematological diseases
Primary prophylaxis of invasive fungal infection in patients with haematological diseases Tunis, May 24 2012 Important questions for antifungal prophylaxis Who are the patients at risk? Which is the risk:
More informationCOPD exacerbation. Dr. med. Frank Rassouli
Definition according to GOLD report: - «An acute event - characterized by a worsening of the patients respiratory symptoms - that is beyond normal day-to-day variations - and leads to a change in medication»
More informationPreventing Nosocomial Pneumonia
Prevention of Nosocomial Pneumonia Andreas F. Widmer, MD,MS,FIDSA,FSHEA Chair Infection Control University of Basel Hospitals & Clinics Basel, Switzerland Preventing Nosocomial Pneumonia Definition & Surveillance
More informationDr Conroy Wong. Professor Richard Beasley. Dr Sarah Mooney. Professor Innes Asher
Professor Richard Beasley University of Otago Director Medical Research Institute of New Zealand Wellington Dr Sarah Mooney Physiotherapy Advanced Clinician Counties Manukau Health NZ Respiratory and Sleep
More informationTerapia della candidiasi addomaniale
Verona 16 marzo 2018 Terapia della candidiasi addomaniale Pierluigi Viale Infectious Disease Unit Teaching Hospital S. Orsola Malpighi Bologna INTRA ABDOMINAL CANDIDIASIS open questions a single definition
More informationPneumonia Community-Acquired Healthcare-Associated
Pneumonia Community-Acquired Healthcare-Associated Edwin Yu Clin Infect Dis 2007;44(S2):27-72 Am J Respir Crit Care Med 2005; 171:388-416 IDSA / ATS Guidelines Microbiology Principles and Practice of Infectious
More informationFungal infection in the immunocompromised patient. Dr Kirsty Dodgson
Fungal infection in the immunocompromised patient Dr Kirsty Dodgson Aims Discuss different types of fungi Overview of types of clinical infections Clinical Manifestations Fungus Includes Moulds Aspergillus
More informationThe use of inhaled antibiotic therapy in the treatment of ventilator-associated pneumonia and tracheobronchitis: a systematic review
Russell et al. BMC Pulmonary Medicine (2016) 16:40 DOI 10.1186/s12890-016-0202-8 RESEARCH ARTICLE Open Access The use of inhaled antibiotic therapy in the treatment of ventilator-associated pneumonia and
More informationVENTILATOR ASSOCIATED PNEUMONIA (VAP)
VENTILATOR ASSOCIATED PNEUMONIA (VAP) Dr.Kolli S.chalam, MD; PDCC. Prof. & Head Dept. of Anesthesiology and Critical care Medicine, Sri Sathya Sai Institute of Higher Medical Sciences, white field, Bangalore-560066.
More informationPneumonia in Older Adults: An Update
Pneumonia in Older Adults: An Update - 2010 Suzanne F. Bradley, M.D. Professor of Internal Medicine Geriatrics & Infectious Diseases University of Michigan Medical School GRECC - VA Ann Arbor HCS ID Hospitalizations
More informationDo PPIs Reduce Bleeding in ICU? Revisiting Stress Ulcer Prophylaxis. Deborah Cook
Do PPIs Reduce Bleeding in ICU? Revisiting Stress Ulcer Prophylaxis Deborah Cook ICU-Acquired Upper GI Bleeding Case series of 300 ICU patients describing stressrelated erosive syndrome Frequent Fatal
More informationDAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES
DAYTON CHILDREN S HOSPITAL CLINICAL PRACTICE GUIDELINES DISCLAIMER: This Clinical Practice Guideline (CPG) generally describes a recommended course of treatment for patients with the identified health
More informationIndre Vengalyte MD¹, Regina Pileckyte MD¹, Laimonas Griskevicius MD PhD 1, 2
ASPERGILLUS GALACTOMANNAN (GM) ANTIGEN IN THE BRONCHOALVEOLAR LAVAGE (BAL) FLUID FOR THE DIAGNOSIS OF INVASIVE PULMONARY ASPERGILLOSIS (IPA) IN HEMATOLOGICAL PATIENTS Indre Vengalyte MD¹, Regina Pileckyte
More informationAerosolized Antibiotics in Mechanically Ventilated Patients
Aerosolized Antibiotics in Mechanically Ventilated Patients Gerald C Smaldone MD PhD Introduction Topical Delivery of Antibiotics to the Lung Tracheobronchitis Aerosolized Antibiotic Delivery in the Medical
More informationCommon Fungi. Catherine Diamond MD MPH
Common Fungi Catherine Diamond MD MPH Birth Month and Day & Last Four Digits of Your Cell Phone # BEFORE: http://tinyurl.com/kvfy3ts AFTER: http://tinyurl.com/lc4dzwr Clinically Common Fungi Yeast Mold
More informationInhaled Antibiotics in Non-CF. Dr Michael Loebinger Host Defence Unit Royal Brompton Hospital London, United Kingdom
Inhaled Antibiotics in Non-CF Dr Michael Loebinger Host Defence Unit Royal Brompton Hospital London, United Kingdom Advantages Increased drug concentrations locally Reduced systemic adverse effects Home
More informationSepsis is an important issue. Clinician s decision-making capability. Guideline recommendations
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock: 2012 Clinicians decision-making capability Guideline recommendations Sepsis is an important issue 8.7%
More informationArmamentarium to prevent VAP. Innovations in Endotracheal Tubes. Armamentarium to prevent VAP. Avoiding accumulation of subglottic secretions
Symposium Trends in de Spoedgevallen en Intensive Zorgen Thomas More Hogeschool, Mechelen, 17 mei 2018 Armamentarium to prevent VAP microaspiration Ventilator-Associated Pneumonia Innovations in Endotracheal
More informationTherapy of Hematologic Malignancies Period at high risk of IFI
Therapy of Hematologic Malignancies Period at high risk of IFI Neutrophils (/mm 3 ) 5 Chemotherapy Conditioning Regimen HSCT Engraftment GVHD + Immunosuppressive Treatment Cutaneous and mucositis : - Direct
More informationProphylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases. Y.L. Kwong Department of Medicine University of Hong Kong
Prophylaxis versus Diagnostics-driven approaches to treatment of Invasive fungal diseases Y.L. Kwong Department of Medicine University of Hong Kong Pathogenic yeast Candida Cryptococcus Trichosporon Pathogenic
More informationSurviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012
本檔僅供內部教學使用檔案內所使用之照片之版權仍屬於原期刊公開使用時, 須獲得原期刊之同意授權 Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock 2012 Definition Sepsis the presence of infection with
More informationBACTERIOLOGY OF POSTOPERATIVE PNEUMONIA EOLE STUDY Dupont H ICM 2003, 29,
Pneumonies: classification Pneumonies communautaires Pneumonies associées aux soins Non nosocomiales Nosocomiales Malade ventilé précoces tardives Malade non ventilé The concept of Health Care Associated
More informationOutcome of patients with hematologic malignancy admitted to the ICU
Outcome of patients with hematologic malignancy admitted to the ICU Geeta Mehta MD, FRCPC Mount Sinai Hospital Toronto, Canada CCCF November 2, 2016 Disclosures Hematologic Malignancy Advances in diagnostics,
More informationBacteriological profile and outcome of Ventilator associated pneumonia in Intensive care unit of a tertiary care centre
ORIGINAL ARTICLE ASIAN JOURNAL OF MEDICAL SCIENCES Bacteriological profile and outcome of Ventilator associated pneumonia in Intensive care unit of a tertiary care centre Ravi K 1, Maithili TM 2, David
More informationLethal pulmonary fungal disease think fungus early
Lethal pulmonary fungal disease think fungus early David W. Denning National Aspergillosis Centre University Hospital of South Manchester The University of Manchester Global Action Fund for Fungal Infections
More informationTREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS. Part I: EMPIRICAL THERAPY
TREATMENT STRATEGIES FOR INVASIVE FUNGAL INFECTIONS Part I: EMPIRICAL THERAPY CAUSES OF DEATH IN PATIENTS WITH MALIGNANCIES NIJMEGEN, THE NETHERLANDS n = 328 BACTERIAL INFECTION FUNGAL INFECTION 7% 36%
More informationBest of Pulmonary Jennifer R. Hucks, MD University of South Carolina School of Medicine
Best of Pulmonary 2012-2013 Jennifer R. Hucks, MD University of South Carolina School of Medicine Topics ARDS- Berlin Definition Prone Positioning For ARDS Lung Protective Ventilation In Patients Without
More informationJean-Yves Fagon,* Jean Chastre, Yves Domart, Jean-Louis Trnuillet, and Claude Gibert
538 Mortality Due to Ventilator-Associated Pneumonia or Colonization with Pseudomonas or Acinetobacter Species: Assessment by Quantitative Culture of Samples Obtained by a Protected Specimen Brush Jean-Yves
More informationTOWARDS PRE-EMPTIVE? TRADITIONAL DIAGNOSIS. GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% β-d-glucan Neg Predict Value 100% PCR
TOWARDS PRE-EMPTIVE? GALACTOMANNAN Sensitivity 61% Specificity 93% Neg Predict Value >95% TRADITIONAL DIAGNOSIS β-d-glucan Neg Predict Value 100% PCR diagnostics FUNGAL BURDEN FIRST TEST POSITIVE FOR ASPERGILLOSIS
More informationChoc septique. Frédéric Pène
Choc septique Frédéric Pène Réanimation Médicale, Hôpital Cochin, AP-HP Université Paris Descartes Institut Cochin, Inserm U1016, CNRS UMR-8104, Département 3i No conflict of interest A 54 y.o. male patient
More informationNIV in hypoxemic patients
NIV in hypoxemic patients Massimo Antonelli, MD Dept. of Intensive Care & Anesthesiology Università Cattolica del Sacro Cuore Rome - Italy Conflict of interest (research grants and consultations): Maquet
More informationFungi GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER NUMBER 53: Fungi Author Moi Lin Ling, MBBS, FRCPA, CPHQ, MBA Chapter Editor Ziad A. Memish, MD, FRCPC, FACP Cover heading - Topic Outline Topic outline
More informationEnterobacter aerogenes
Enterobacter aerogenes Piagnerelli M 1, Carlier E 1, Deplano A 3, Lejeune P 1, Govaerts D 2 1 Departments of Intensive Care and 2 Microbiology, A. Vésale Hospital. 6110 Montigny-le-Tilleul. 3 Department
More informationThe promise of nebulized antibiotic therapy
1 st ATHENA International Conference Athens, 19-20 November 2015 Let s Talk About Inhaled Antibiotics Inhaled Antibiotics: The Story Stijn BLOT Dept. of Internal Medicine Faculty of Medicine & Health Science
More informationGUIDE TO INFECTION CONTROL IN THE HOSPITAL. Carbapenem-resistant Enterobacteriaceae
GUIDE TO INFECTION CONTROL IN THE HOSPITAL CHAPTER 47: Carbapenem-resistant Enterobacteriaceae Authors E-B Kruse, MD H. Wisplinghoff, MD Chapter Editor Michelle Doll, MD, MPH) Topic Outline Key Issue Known
More informationDisclosure. Hospira Pharmaceuticals. Unrestricted research funding Honoraria for CME education administered via France Foundation
Disclosure Hospira Pharmaceuticals Unrestricted research funding Honoraria for CME education administered via France Foundation Economics in Sedation: Responsible Use of the ICU Budget John W. Devlin,
More information